Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

On Wednesday, William Blair initiated coverage on Kyverna Therapeutics Inc. KYTX, a small-cap biotechnology company focused on cell therapies for autoimmune disorders. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through late-stage clinical development with registrational trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis. Topline data for the registrational Phase 2 trial of KYV-101 in stiff person syn ...